AlzeCure Pharma AB (publ)

Stockholm Stock Exchange ALZCUR.ST

AlzeCure Pharma AB (publ) Operating Income Margin for the year ending December 31, 2023

AlzeCure Pharma AB (publ) Operating Income Margin is NA for the year ending December 31, 2023. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.
Key data
Date Operating Income Margin EBT Margin Net Income Margin EBITDA Margin
Market news
Stockholm Stock Exchange: ALZCUR.ST

AlzeCure Pharma AB (publ)

CEO Mr. Martin Jönsson
IPO Date Nov. 28, 2018
Location Sweden
Headquarters HAelsovAegen 7
Employees 11
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.

StockViz Staff

January 15, 2025

Any question? Send us an email